SCHEMBL25093457

SCHEMBL25093457

CC(C)c1ccc(C(=O)NC2CC2)nc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ TSHR P16473 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ DPP4 P27487 2/20 0.43
▸ PARP1 P09874 1/20 0.41
▸ PRKAA2 P54646 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CNR2 P34972 3/20 0.40
▸ SMYD3 Q9H7B4 1/20 0.40
▸ HTR1A P08908 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ HTR7 P34969 1/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ HSD11B1 P28845 2/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ CD38 P28907 1/20 0.39
▸ CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25912411 0.81 ABL1 (0.49) NPC1RAB9ADPP4PARP1PRKAA2
SCHEMBL25093421 0.80 BRD4 (0.42) NPC1RAB9ASMN1; SMN2PARP1BRD4
SCHEMBL25912472 0.79 DPP4 (0.47) NPC1RAB9ASMN1; SMN2DPP4PARP1
SCHEMBL24959363 0.77 APP (0.43) —
SCHEMBL24960094 0.74 NPC1 (0.48) NPC1RAB9ATSHRSMN1; SMN2TDP1
SCHEMBL105413 0.72 TAS1R3 (0.53) NPC1RAB9ADPP4CNR2
SCHEMBL31510149 0.71 SMYD3 (0.46) DPP4PARP1PRKAA2CNR2SMYD3
SCHEMBL25698486 0.71 CHRM4 (0.49) NPC1RAB9ASMN1; SMN2DPP4PARP1
SCHEMBL25150683 0.71 MALT1 (0.41) PRKAA2ALDH1A1CNR2
SCHEMBL104332 0.71 SMN1; SMN2 (0.49) NPC1RAB9ATSHRSMN1; SMN2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 — — WO disclosed
US-20230128041-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-04-27 — — US disclosed
US-20230128041-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-04-27 — — US disclosed
US-11591331-B2 PARP1 inhibitors and uses thereof XINTHERA, INC. (US) 2023-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128041-A1 PARP1 INHIBITORS AND USES THEREOF PARP1, PARP11, PARP12 NPC1 2940/4885RAB9A 3330/4885TSHR 4575/4885
US-11591331-B2 PARP1 inhibitors and uses thereof PARP1, PARP11, PARP12 NPC1 2940/4885RAB9A 3330/4885TSHR 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback